CRANBURY, N.J., Oct. 17, 2019 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN) announced that John Dodd, Ph.D., Palatin's Vice President of
Pre-Clinical Development, provided a presentation on Palatin's oral
colon delivery formulation, PL8177 in development for the treatment
of ulcerative colitis, at the 7th CPC Symposium on
Peptide Therapeutics in Hangzhou,
China. Dr. Dodd was invited by symposium organizers to speak
about the challenges of peptide drug development. His presentation
outlined how the oral colon delivery formulation of PL8177
effectively addresses the issues of peptide drug delivery and
included efficacy data from preclinical ulcerative colitis studies
and safety data from Phase 1 clinical studies.
"Palatin has taken significant steps in developing an oral
delivery formulation of PL8177 for treatment of ulcerative
colitis," said Carl Spana, Ph.D.,
President and CEO of Palatin. "We look forward to leveraging our
experience and expertise in melanocortin product development as we
continue with our PL8177 program. The encouraging safety profile,
preclinical efficacy, and novel mechanism of action of PL8177 could
compete well in the treatment of ulcerative colitis and other
inflammatory bowel diseases."
PL8177 is a potent melanocortin receptor 1 agonist that has
demonstrated excellent safety in early non-clinical and clinical
studies. The oral formulation has not resulted in any detectable
systemic absorption, suggesting a very low probability of any
safety issues in human efficacy trials. The oral delivery
formulation successfully delivered PL8177 to the human colon lumen.
Preclinical models of inflammatory bowel disease demonstrated
delivery of PL8177 to rat colon lumen with excellent potency and
efficacy.
Palatin currently plans to initiate human Phase 2
proof-of-principle studies in ulcerative colitis in the first half
of 2020.
About PL8177
PL8177 is a synthetic cyclic heptapeptide
with demonstrated efficacy in animal inflammatory bowel disease
models. Palatin has developed an oral formulation for delivery of
PL8177 to the lumen of the colon that has been validated in animal
studies. PL8177 is a potent agonist at the human melanocortin
receptor 1, with sub-nanomolar affinity binding and EC50
functional values.
About Ulcerative Colitis
Ulcerative colitis is a
chronic disease of the large intestine (colon), with inflammation
and ulcerations that can cause significant abdominal pain,
persistent diarrhea, loss of appetite and other symptoms. Over
700,000 individuals in the United
States are affected by ulcerative colitis, with over 350,000
diagnosed with moderate-to-severe disease. Existing treatments are
not effective in a large portion of patients with
moderate-to-severe ulcerative colitis, with some severe cases
resulting in surgical removal of the colon.
About Palatin Technologies, Inc.
Palatin
Technologies, Inc. is focused on developing drugs that modulate the
melanocortin system to treat diseases and conditions with
significant unmet medical need and commercial potential. Palatin's
strategy is to develop products and then form marketing
collaborations with industry leaders in order to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.Palatin.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/palatin-presents-on-pl8177-oral-colon-delivery-formulation-for-ulcerative-colitis-at-the-7th-cpc-symposium-on-peptide-therapeutics-300940277.html
SOURCE Palatin Technologies, Inc.